drugset / Trial / NCT00325715

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

NCT00325715

Phase 1 Completed 150 enrolled Allergan
RandomizedParallel-groupSingle-blindPrevention

Summary

AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

Timeline

Start
2006-04
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AGN 201904 Small molecule
Comparator Esomeprazole Small molecule

Indications